A dose escalation, safety, and tolerability study of denibulin [MN 029] administered every seven days in subjects with advanced metastatic solid tumors

Trial Profile

A dose escalation, safety, and tolerability study of denibulin [MN 029] administered every seven days in subjects with advanced metastatic solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2013

At a glance

  • Drugs Denibulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MediciNova
  • Most Recent Events

    • 06 Oct 2013 Status changed from recruiting to completed.
    • 09 Nov 2007 Positive results have been reported.
    • 31 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top